Health
bioMérieux: BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 Obtains De Novo FDA Authorization – Business Wire
Regulatory News: bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary
MARCY LÉTOILE, France–(BUSINESS WIRE)–Regulatory News:
bioMérieux (Paris:BIM), a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel. This panel allows for the detection of 22 viral and bacterial pathogens responsible for respiratory infections, including SARS-CoV-2 (the cause…
-
General15 hours ago‘We are here for you’: PM to bring help to flood zones
-
General13 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News21 hours agoStudents say new facility would be better in rural areas of Queensland
-
Noosa News9 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland